Abdul Wahab, Roshaida
Al-Ruwaily, Heshma
Coleman, Therese
Heneghan, Helen
Neff, Karl
le Roux, Carel W.
Fallon, Finian
Funding for this research was provided by:
University College Dublin
Article History
Received: 18 August 2021
Revised: 9 March 2022
Accepted: 9 March 2022
First Online: 19 March 2022
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: ClR reports grants from the Irish Research Council, Science Foundation Ireland, Anabio, and the Health Research Board. He serves on advisory boards of Novo Nordisk, Herbalife, GI Dynamics, Eli Lilly, Johnson & Johnson, Sanofi Aventis, AstraZeneca, Janssen, Bristol-Myers Squibb, Glia, and Boehringer Ingelheim. ClR is a member of the Irish Society for Nutrition and Metabolism outside the area of work commented on here. He is the chief medical officer and director of the Medical Device Division of Keyron since January 2011. Both are unremunerated positions. ClR was a previous investor in Keyron, which develops endoscopically implantable medical devices intended to mimic the surgical procedures of sleeve gastrectomy and gastric bypass. He continues to provide scientific advice to Keyron for no remuneration. The other authors declare that they have no conflict of interest.